Orthocell (OCC) Q1 2025 TU earnings summary

Executive summary

• Achieved a second consecutive quarter of record revenue, reaching $2.03 million for the September 2024 quarter, up 7.96% from the previous quarter and 14.99% year-over-year.

• Strong market traction for Striate+ and Remplir products, with expanding adoption among surgeons and new regulatory approvals in key international markets.

• Maintained a robust cash position of $18.4 million, supporting ongoing global expansion and product development.

Financial highlights

• Quarterly revenue grew to $2.03 million, a 7.96% increase from $1.88 million in June 2024 and a 14.99% rise from $1.76 million in September 2023.

• Compound quarterly revenue growth rate averaged 9.10% over the last eight quarters.

• Net cash outflow from operating activities was $(1.99) million for the quarter.

• Cash receipts from customers totaled $1.14 million for the quarter.

Outlook and guidance

• Anticipates first sales of Remplir in Singapore in Q1 CY25 following regulatory approval.

• US 510(k) market authorisation application for Remplir on track for submission in Q4 CY24, with sales expected soon after approval.

• Further regulatory applications for Striate+ and Remplir planned in Brazil, Singapore, Canada, Thailand, and EU/UK within the next 6-12 months.